Seeking Alpha

Merck (MRK +1.9% premarket) says one of its two migraine drugs was largely safe and effective in...

Merck (MRK +1.9% premarket) says one of its two migraine drugs was largely safe and effective in a Phase III trial, but pulled the second due to reports of liver problems. (PR)
From other sites
Comments (2)
  • overbet
    , contributor
    Comments (37) | Send Message
     
    no shares have traded in mrk yet. how can it be up? and there is no active market. the best bid is down .20 from pc
    10 Sep 2009, 09:12 AM Reply Like
  • Tony Petroski
    , contributor
    Comments (6373) | Send Message
     
    I agree with overbet. What is the source of this premarket move?
    10 Sep 2009, 09:20 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs